21 May 2013
Keywords: strong, ph, ii, data, biogen, idec, bg-12
Article | 05 June 2006
US drugmaker Biogen Idec has reported positive results from a Phase II study designed to evaluate the efficacy and safety ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 June 2006
12 June 2006
29 May 2006
© 2013 thepharmaletter.com